Financial Contrast: Innate Pharma (OTCMKTS:IPHYF) vs. Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) and Innate Pharma (OTCMKTS:IPHYF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations for Ionis Pharmaceuticals and Innate Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1	3	16	1	2.81
Innate Pharma	0	0	0	0	0.00

Ionis Pharmaceuticals presently has a consensus price target of $89.00, indicating a potential upside of 25.72%. Given Ionis Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Innate Pharma.

Earnings and Valuation

This table compares Ionis Pharmaceuticals and Innate Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944.00 million	12.39	-$381.39 million	($2.44)	-29.01
Innate Pharma	$21.77 million	5.29	-$53.53 million	N/A	N/A

Innate Pharma has lower revenue, but higher earnings than Ionis Pharmaceuticals.

Profitability

This table compares Ionis Pharmaceuticals and Innate Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-40.36%	-68.82%	-12.34%
Innate Pharma	N/A	N/A	N/A

Institutional & Insider Ownership

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500.

Summary

Ionis Pharmaceuticals beats Innate Pharma on 8 of the 13 factors compared between the two stocks.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.